Verifying…
Home / Drug A–Z / Hidrasec Granules for Oral Suspension (Children)## (check pack size)

Hidrasec Granules for Oral Suspension (Children)## (check pack size)

NAFDAC Reg. No. B4-7102 · Drug

Registered with NAFDAC — registration activeAs of 5 November 2026 · synced automatically from official sources.
Product
Hidrasec Granules for Oral Suspension (Children)## (check pack size)
NAFDAC number
B4-7102
Active ingredient
Racecadotril
Strength
30 mg
Form
Granules for suspension
Pack size
1 x 30's, 2 x 8's (in sachets)
Manufacturer
Not listed
Applicant (holder)
Phillips Pharmaceuticals (Nigeria) Limited
Approved
26 Apr 2023
Status
Active View on NAFDAC ↗
Registration valid to
25 Apr 2028
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Hidrasec Granules for Oral Suspension (Children)## (check pack size) is on the NAFDAC register with an active registration (B4-7102). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Hidrasec Granules for Oral Suspension (Children)## (check pack size) is used for

From the official U.S. FDA label for Hidrasec Granules for Oral Suspension (Children)## (check pack size), the active ingredient registered with NAFDAC.

What it is used for

Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium for delayed-release oral suspension is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing a …

Possible side effects

The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions ( 5.2 )] Clostridium difficile- Associated Diarrhea [see Warnings and Precautions ( 5.3 )] Bone Fracture [see Warnings and Precautions ( 5.4 )] Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.5 )] Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions ( 5.6 )] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions ( 5.7 )] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions ( 5.8 )] Fundic Gland Polyps [see Warnings and Precautions ( 5.10 )] Most common adverse reactions a …

Do not use if

Pantoprazole sodium for delayed-release oral suspension is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6 )] . …

Warnings

Gastric Malignancy: In adults, symptomatic response does not preclude presence of gastric malignancy. Consider additional follow-up and diagnostic testing. ( 5.1 ) Acute Tubulointerstitial Nephritis : Discontinue treatment and evaluate patients. ( 5.2 ) Clostridium difficile- Associated Diarrhea : PPI therapy may be associated with increased risk of Clostridium difficile- associated diarrhea. ( 5.3 ) Bone Fracture : Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary Available data from published observational studies did not demonstrate an association of major malformations or other adverse pregnancy outcomes with pantoprazole. In animal reproduction studies, no evidence of adverse development outcomes was observed with pantoprazole. …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Hidrasec Granules for Oral Suspension (Children)## (check pack size)

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Hidrasec Granules for Oral Suspension (Children)## (check pack size)

What is in Hidrasec Granules for Oral Suspension (Children)## (check pack size)?

Hidrasec Granules for Oral Suspension (Children)## (check pack size) contains Racecadotril (30 mg), as granules for suspension, according to its NAFDAC registration record.

Is Hidrasec Granules for Oral Suspension (Children)## (check pack size) registered with NAFDAC?

Yes. Hidrasec Granules for Oral Suspension (Children)## (check pack size) is listed on the NAFDAC register under registration number B4-7102, and its registration is active as of 5 November 2026.

Has Hidrasec Granules for Oral Suspension (Children)## (check pack size) been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Hidrasec Granules for Oral Suspension (Children)## (check pack size) in our automatically synced alert list.

How can I check that my pack of Hidrasec Granules for Oral Suspension (Children)## (check pack size) is genuine?

Run a free authenticity scan with the NAFDAC number B4-7102, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Hidrasec Granules for Oral Suspension (Children)## (check pack size) used for?

Pantoprazole sodium for delayed-release oral suspension is indicated for: Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( (Summarised from the official U.S. FDA label for Hidrasec Granules for Oral Suspension (Children)## (check pack size). Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Hidrasec Granules for Oral Suspension (Children)## (check pack size)? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.